Just caught wind that BioRestorative got some solid backing from the FDA on their BRTX-100 program. They had a Type B meeting with the agency and came out of it without any red flags on the safety side - pretty significant for a cell therapy in this space. The company's been running a Phase 2 trial with 99 patients across 15 sites and the data apparently checked out well enough that FDA signed off on their proposed Phase 3 design. What's interesting is they got Fast Track status back in February, which basically means the FDA is treating this as a priority given the unmet need in chronic lumbar disc disease. That opens doors to expedited review pathways down the line. They're now gearing up Phase 3 activities with plans to file the investigational new drug application later this year. BRTX-100 itself is a cell-based therapy engineered to work in areas with poor blood flow - the mechanism makes sense for disc degeneration. The stock has been volatile, trading between $0.58 and $2.50 over the past year, currently sitting around $0.48. Regulatory wins like a clean Type B meeting can shift sentiment, though biotech is always a longer play. Worth watching how the Phase 3 enrollment develops.